Biocardia Inc (BCDA)

US · Healthcare · Biotechnology

$1.11-11.20%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Net profit

$-1.6M

EPS

$-0.13

EPS estimate

$-0.19

EPS came in at -0.13 against a street estimate of -0.19 — a beat of 31.6%.

Market cap

$16.7M

Forward P/E

0.0

P/B

6.22

Book value

$0.18

EPS (TTM)

$-0.59

52-week high

$2.27

52-week low

$0.75

50-day MA

$0.98

200-day MA

$1.14

Beta

0.55

Analysts rate Biocardia Inc a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $15.50.

Insiders

23.19%

Institutions

9.50%

Fund	Stake
CM Management, LLC	0.86%
Vanguard Capital Management, LLC	0.82%
Geode Capital Management, LLC	0.62%
Vanguard Fiduciary Trust Co	0.44%
Citadel Advisors Llc	0.42%
Susquehanna International Group, LLP	0.26%
Pingora Partners LLC	0.24%
Brown Advisory Holdings Inc	0.23%

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Biocardia Inc — free to start.

Data updated 2026-09-18.